278 related articles for article (PubMed ID: 17718239)
1. [The deleterious effect of certain surface active agents on the ocular surface].
Ravet O
Bull Soc Belge Ophtalmol; 2007; (304):145-9. PubMed ID: 17718239
[TBL] [Abstract][Full Text] [Related]
2. [Effects of preservatives in anti-glaucoma agents on the ocular surface].
Potop V
Oftalmologia; 2009; 53(2):92-6. PubMed ID: 19697847
[TBL] [Abstract][Full Text] [Related]
3. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review.
Yee RW
Curr Opin Ophthalmol; 2007 Mar; 18(2):134-9. PubMed ID: 17301615
[TBL] [Abstract][Full Text] [Related]
4. Preservatives in eyedrops: the good, the bad and the ugly.
Baudouin C; Labbé A; Liang H; Pauly A; Brignole-Baudouin F
Prog Retin Eye Res; 2010 Jul; 29(4):312-34. PubMed ID: 20302969
[TBL] [Abstract][Full Text] [Related]
5. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
6. [Influence on ocular surface and intraocular pressure of switching from preservative-containing to preservative-free carteolol hydrochloride ophthalmic solution].
Chikama T; Araie M; Nishida T
Nippon Ganka Gakkai Zasshi; 2013 May; 117(5):419-26. PubMed ID: 23855234
[No Abstract] [Full Text] [Related]
7. [Advances in preservative-free glaucoma drops].
Stefan C; Pop A; Cojocaru I
Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063
[TBL] [Abstract][Full Text] [Related]
8. [Glaucoma and ocular surface].
Stefan C; Cojocaru I; Pop A
Oftalmologia; 2011; 55(1):30-3. PubMed ID: 21774383
[TBL] [Abstract][Full Text] [Related]
9. Unilateral drug-induced ocular pseudopemphigoid.
Gibran SK
Eye (Lond); 2004 Dec; 18(12):1270. PubMed ID: 15044940
[No Abstract] [Full Text] [Related]
10. Effects of topical antiglaucoma medications on corneal epithelium as evaluated by gene expression patterns.
Okada Y
Cornea; 2007 Oct; 26(9 Suppl 1):S46-54. PubMed ID: 17881916
[TBL] [Abstract][Full Text] [Related]
11. [Managing treatment side effects: the respective roles of the active ingredient and the preservative].
Aptel F; Denis P; Baudouin C
J Fr Ophtalmol; 2011 Jun; 34(6):409-12. PubMed ID: 21511364
[TBL] [Abstract][Full Text] [Related]
12. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
Baudouin C
Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
[TBL] [Abstract][Full Text] [Related]
13. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
Kahook MY; Noecker RJ
Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
[TBL] [Abstract][Full Text] [Related]
14. Barriers to glaucoma drug delivery.
Ghate D; Edelhauser HF
J Glaucoma; 2008 Mar; 17(2):147-56. PubMed ID: 18344762
[TBL] [Abstract][Full Text] [Related]
15. [Ocular intolerance to antiglaucoma medications is underestimated].
Bresson-Dumont H
Bull Soc Belge Ophtalmol; 2010; (315):47-53. PubMed ID: 21114054
[TBL] [Abstract][Full Text] [Related]
16. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy.
Soltau JB
J Glaucoma; 2004 Aug; 13(4):348; author reply 348. PubMed ID: 15226666
[No Abstract] [Full Text] [Related]
17. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery.
Jiao J
Adv Drug Deliv Rev; 2008 Dec; 60(15):1663-73. PubMed ID: 18845195
[TBL] [Abstract][Full Text] [Related]
18. Preservative-free treatment in glaucoma: who, when, and why.
Stalmans I; Sunaric Mégevand G; Cordeiro MF; Hommer A; Rossetti L; Goñi F; Heijl A; Bron A
Eur J Ophthalmol; 2013; 23(4):518-25. PubMed ID: 23483513
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs?
Baudouin C
Int J Clin Pharmacol Res; 1996; 16(1):29-41. PubMed ID: 9001927
[TBL] [Abstract][Full Text] [Related]
20. [Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs].
He XG
Zhonghua Yan Ke Za Zhi; 2011 Feb; 47(2):101-4. PubMed ID: 21426837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
